Floatz logo

Thalidomide

Chronic Prostatitis

Kenneth Peters, MDSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Chronic Prostatitis cohort.

Asset / SponsorPhaseRating
Ningmitai
Xintian Pharmaceutical
Phase 4BBB
Selenium
Clinica Urologica Molinette - Città della Saliute e della Scienza
Phase 4BB
Serenoa repens extract
Clinica Urologica Molinette - Città della Saliute e della Scienza
Phase 4BB
PALMITIC MONOETHANOLAMIDE
Clinica Urologica Molinette - Città della Saliute e della Scienza
Phase 4BB
Tamsulosin
Xintian Pharmaceutical
Phase 4BB

View all 20 →

Same molecule, other indications

Thalidomide is also rated in:

central nervous system neoplasmDormant
BB
Indicative ·
70 / 100
View asset →
plasma cell myelomaDormant
BB
Indicative ·
68 / 100
View asset →
uveal melanomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →